Sharp Therapeutics Corp.
SHRX · V · Healthcare / Biotechnology
1.37CAD+0.00 (0.00%)
Price History
Full chartMarket Stats
Previous Close1.37
Open1.37
Day Range1.37 – 1.37
52-Week Range0.91 – 5.00
Volume0
Market Cap41.20M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.28
Dividend Yield0.00%
Beta-1.15
50-Day Avg1.08
200-Day Avg1.74
About
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform that captures data for AlloChem compounds in CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.
Company Details
- SectorHealthcare
- IndustryBiotechnology
- CEODr. Scott F. Sneddon J.D., Ph.D.
- Employees0
- Headquarters2403 Sidney Street, Pittsburgh, PA, United States, 15203, Canada
- Websitehttps://sharptx.com
Leadership
- Dr. Scott F. Sneddon J.D., Ph.D.CEO, Chief Science Officer & Director · b. 1963
- Mr. Edward Jonasson CA CPACFO & Corporate Secretary · b. 1969
- Mr. Marcel P. Bruchez Ph.D.Scientific Co-Founder & CTO
- Dr. Alan S. Waggoner Ph.D.Scientific Co-Founder and Chief Architect
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Market Cap41.20M
Enterprise Value46.28M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book32.69
EPS-0.28
Book Value-0.1021
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-5.58M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-3762.21%
Return on Assets-131.63%
Shares Outstanding30.08M
Shares Float17.62M
Beta-1.15
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%
Stock Splits
- Jan 27, 20251:10